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CMR-Veriﬁed Interstitial
Myocardial Fibrosis as a
Marker of Subclinical Cardiac
Involvement in
LMNA Mutation Carriers
Lamin A/C (LMNA) gene mutation, identified in 10% of
familial dilated cardiomyopathy (DCM) patients, is associated
with an increased risk of sudden cardiac death (SCD), which
may be the first clinical manifestation (1). Myocardial fibrosis
(MF) has been identified in the hearts of LMNA mutation
arriers experiencing arrhythmias or conduction disturbances,
rrespective of left ventricular (LV) dilation and/or dysfunction
2). Thus, MF may be a precocious primary phenomenon
esponsible for the subsequent development of electrical insta-
ility and LV dysfunction. Cardiovascular magnetic resonance
CMR) allows the depiction of gross MF by late gadolinium
nhancement (LGE), whereas extracellular/extravascular vol-
me (ECV) fraction of the myocardium by pre- and post-
ontrast T1 mapping was recently demonstrated to detect
nterstitial MF (3). We aimed to investigate the incidence and
attern of MF using comprehensive CMR in LMNAmutation
arriers.
We prospectively studied 7 families whose probands with
he DCM phenotype were referred to our hospital between
009 and 2011. We found 5 missense, 1 frame, and 1 splicing
utations (Online Appendix). All LMNA mutation carriers
underwent biohumoral assays (hematocrit, N-terminal pro–B-
type natriuretic peptide, plasma catecholamine, aldosterone,
and plasma renin activity [PRA]), 12-lead electrocardiogra-
phy, 24-h Holter monitoring, a cardiopulmonary exercise test,
and CMR. All 6 probands received beta-blocker and/or an
angiotensin-converting enzyme inhibitor therapy. A group of
16 age-matched healthy volunteers without a clinical history of
cardiovascular disease was recruited as controls and underwent
CMR, 12-lead electrocardiography, and blood sampling for
hematocrit determination.
Participants were examined by 1.5-T unit (CVi, GE-
Healthcare, Milwaukee, Wisconsin). Standard protocols for
LV volume and function and late gadolinium enhancement
(LGE) were performed. For myocardial ECV determina-
tion, T1 values of myocardium and blood cavity were
measured in a single mid ventricular short-axis slice using
modified-cine inversion-recovery sequence before and at
fixed time intervals (5, 10, and 15 min) after a bolus of
contrast agent (Gadodiamide-OMNISCAN,0.2 mmol/kg).
Protocols, sequence parameters, T1-mapping, and myocar-ial ECV calculation are detailed in the Supplemental
aterial.
Baseline characteristics of LMNA mutation carriers and
ealthy controls are outlined in Tables 1 and 2, respectively.
MNA mutation carriers and healthy controls showed
omparable age (46  18 vs. 45  13 years, p  0.717) and
ody mass index (23.4  4.1 vs. 24.0  3.9 kg/m2, p 
.659), although a lower prevalence of male sex was
bserved in LMNA mutation carriers compared with
ealthy controls (37% vs. 75%, p  0.042). LMNA muta-
ion carriers had slightly larger LV end-diastolic volume
nd lower ejection fraction than healthy controls (87  20
s. 76  12 ml/m2 and 60  8% vs. 68  5%, respectively;
oth p  0.05) (Online Fig. 1).
Five (26%) LMNA mutation carriers with an enlarged and
ysfunctional left ventricle were older (67  8 vs. 39  14
ears) and had a higher pro–B-type natriuretic peptide level
median 333 ng/l [25th to 75th percentiles: 62 to 1,943] vs.
edian 66 ng/l [25th to 75th percentiles: 29 to 107]) than
MNA mutation carriers with normal LV dimension and
unction (both p  0.05). In all LMNA mutation carriers,
RA and catecholamine levels were within normal range,
hereas the plasma aldosterone level was close to the upper
ormal limit (median 140 pg/ml [25th to 75th percentiles: 75
o 170], reference values: 20 to 180 pg/ml). Eight LMNA
utation carriers (42%) showed myocardial LGE with a
atchy (n  3) or mid wall (n  5) pattern. In LMNA
mutation carriers, LGE was more frequently detected in
carriers with LV dysfunction (4 of 5 patients, 80%) compared
with those with normal LV dimension and function (4 of 14
[29%], p  0.05). Myocardial LGE was more common in
carriers with first-degree atrioventricular block (4 of 5 [80%])
than those with normal atrioventricular conduction (1 of 14
[7%], p  0.05).
Myocardial ECV was higher in LMNA mutation carriers
than healthy controls (28.0  2.9% vs. 22.7  3.0%, p 
.001) even after excluding LV segments with LGE (27.9 
.7% vs. 22.7 3.5%; p 0.001). Myocardial ECV remained
igher in LMNAmutation carriers after excluding carriers with
GE (28.6  3.2% vs. 22.7  3.5%, p  0.001) or overt LV
ysfunction (28.6  2.9%, p  0.001) (Online Fig. 1).
We demonstrated that interstitial MF represents a subclin-
ical marker of cardiac involvement in genotype-positive
LMNA carriers, likely determined by the expression of the
mutated gene. This was substantiated by the fact that LMNA
mutation carriers showed increased myocardial ECV than
healthy controls also when the analysis was confined to carriers
without LV dysfunction, electrical abnormalities, or LGE.
Additionally, in LMNA mutation carriers, the PRA and
aldosterone levels were not significantly increased, indicating
that interstitial MF was unlikely related to the activation of the
renin-angiotensin-aldosterone axis. These findings are concor-
dant with previous studies reporting that LMNA mutation is
 pe
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Letters to the Editor 125associated with myocardial and skeletal muscle fibrosis (2), indicat-
ing that MF may occur as primary phenomenon due to mutated
gene expression. On the other hand, myocardial LGE was more
common in carriers with LV dysfunction and/or electrical distur-
bances rather representing an unspecific marker of myocardial
damage (4).
Table 1. Baseline Characteristics of LMNA Mutation Carriers
Case
Sex,
M/F
Age,
yrs
BMI,
kg/m2
CPK,
U/l (rv
<270)
NT-proBNP ng/l
(rv <157)
1 Proband M 62 24.2 62 333 S
2 Proband M 76 22.3 91 943 S
3 Proband F 67 28.3 95 81
4 Proband F 74 22.7 72 3023 S
5 Proband M 58 24.1 350 91 S
6 Proband F 43 24.5 50 533 S
7 Relative M 57 30.3 135 42
8 Relative M 39 24.1 129 25
9 Relative F 43 17.7 53 13
10 Relative M 35 23.6 172 64 S
11 Relative F 28 20.5 70 72
12 Relative F 43 20.8 72 50
13 Relative F 13 19.1 88 30
14 Relative F 64 32.5 77 101
15 Relative M 33 28.4 487 12
16 Relative F 38 18.9 290 124
17 Relative F 51 22.0 66 266
18 Relative F 41 23.6 112 68
19 Relative F 18 17.7 70 43
*Lown classiﬁcation of ventricular arrhythmias: isolated monomorphic ventricular beats 720
(class 4a), ventricular tachycardias (class 4b), ventricular beats with R/T phenomenon (class 5
AVB  ﬁrst-degree atrioventricular block; BMI  body mass index; CPK  creatine phosphok
anterior fascicular block; LBBB left bundle branch block; LVEF, left ventricular ejection fraction
peptide; rv  range value; SR  sinus rhythm; SVT  sustained ventricular tachycardia; VO2
Table 2. Baseline Characteristics of Healthy Controls
Case Sex M/F Age, yrs BMI, kg/
1 Control F 34 17.9
2 Control M 72 26.6
3 Control M 21 22.8
4 Control M 61 25.7
5 Control M 29 20.8
6 Control M 51 19.6
7 Control F 28 24.2
8 Control M 36 19.8
9 Control M 46 33.3
10 Control M 51 27.4
11 Control M 40 25.1
12 Control M 40 25.9
13 Control F 46 19.3
14 Control F 63 26.3
15 Control M 50 23.5
16 Control M 45 26.4COPD  chronic obstructive pulmonary disease; other abbreviations as in Table 1.In conclusion, CMR showed that MF is an intrinsic feature of
LMNA cardiomyopathy ranging from interstitial to gross MF.
Interstitial MF may represent a subclinical marker preceding the
overt structural, functional, and electrical abnormalities. In contrast,
gross MF is more commonly detected in carriers already expressing
the typical cardiac phenotype.
face ECG
24-h Holter Lown
class* (1–5)
LVEF,
%
Peak VO2
ml/min/kg Comorbidities
VB, LBBB 4a 49 24.1 Dyslip
VB, LBBB 4b 49 23.7 HT
SR 1 54 18.1
VB, LBBB 4b (SVT) 51 — Dyslip
VB 4b (SVT) 56 24.2
AFB 4b (SVT) 58 15
SR 4b 52 24.9 Dyslip
SR 1 58 41
SR 1 75 33.7
VB 4b 70 33.6
SR 1 60 38.5
SR 0 61 21.9
SR 0 71 26.3
SR 1 67 20.6 Dyslip,HT
SR 1 67 29.3
SR 4b 62 28.2
SR 1 66 27.2
SR 4a 60 23.9
SR 1 57 29
lass 1), 720/d (class 2), isolated polymorphic ventricular beats (class 3), ventricular couplets
tients with sustained ventricular tachycardia are indicated.
; ECG  electrocardiogram; Dyslip  dyslipidemia; F  female; HT  hypertension; LAFB, left
ardiovascular magnetic resonance; Mmale; NT-proBNP N-terminal pro–B-type natriuretic
ak oxygen consumption.
Surface ECG LVEF, % Comorbidities
SR 66
SR 71 Mild COPD
SR 78
SR 79
SR 68
SR 71
SR 72
SR 64
SR 65
SR 65
SR 70
SR 62
SR 72
SR 68 Mild COPD
SR 61
SR 66Sur
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Lipid-Rich Versus Fibrous
Intimal Hyperplasia in
Transplant Vasculopathy
In the June 2012 issue of iJACC, Hou et al. (1) reported that the
optical coherence tomography (OCT), compared with intravascular
ultrasound (IVUS), was more sensitive for early detection of cardiac
Figure 1. Diffuse Cardiac Allograft Vasculopathy
Intravascular ultrasound (IVUS) (A), angiography (B), and near-infrared spectrosc
18-year-old male patient 11 years after heart transplantation for dilated cardiom
sectional image. White lines (B and C) represent a region of the angiogram co
received immunosuppressive therapy with lipid-lowering agents (tacrolimus, pr
diffuse disease especially prominent in the mid LAD. Pruning of the secondary
and NIRS chemogram lipid core burden index  0.llograft vasculopathy (CAV). Mean intimal hyperplasia (IH) was
80 m. IH thickness 150 m accounted for 31% of assessable
segments, which is underresolution of IVUS. Lipid-rich plaques
(LCPs) with thin fibrous caps were found by OCT in 43% of
transplant recipients.
The incidence of CAV is as high as 50% at 5 years after
transplantation, and survival is substantially curtailed after the
diagnosis of CAV is established. Despite the significant progress in
the control of cellular rejection, the evolution of graft vasculopathy
has continued unabated. Aggressive control of established risk
factors and some of the newer antiproliferative agents remain the
cornerstone of CAV management. Use of statins has demonstrated
an outcome benefit by cholesterol reduction and also by the
cholesterol-independent immune-modulating effect on the natural
killer cells; the immunomodulatory efficacy of statins is exaggerated
in the presence of a calcineurin inhibitor (2).
We need to use sensitive tools for the diagnosis and screening of
CAV to develop novel treatment strategies. Due to the denervation of
transplanted hearts, symptoms of vasculopathy are usually not obvious.
Therefore, coronary angiography is repeated annually in most trans-
plantation centers. However, information obtained from angiography
is often limited because CAV is diffuse. IVUS is able to accurately
image the 3 vessel wall layers, and the IH evaluation by IVUS
correlates with the occurrence of adverse events post-transplantation.
IH of500m in the first year after transplantation predicts increased
ortality, myocardial infarction, and late development of severe CAV
nd heart failure (3). Further differentiation of fibrous from lipid-rich
eointima offers a significant prognostic and therapeutic advantage.
lthough gray-scale IVUS is unable to determine the etiology of
AV, intravascular OCT generates cross-sectional vessel images with
0-fold higher resolution than IVUS and with a more precise charac-
erization of IH. Assessment of lipid-rich lesions is also possible by
ear-infrared spectroscopy (NIRS), in which the NIRS measurements
re presented as a chemogram with the probability of a lipid core
ontaining plaques on a color scale from red to yellow (0 for red, 1 for
(NIRS) (C) scans of the medial left anterior descending artery (LAD) in an
athy. The white arrow (B) indicates the location of the presented IVUS cross-
onding to the NIRS scan. Yellow lines (C) represent 2-mm blocks. The patient
sone, mycophenolate, aspirin, and simvastatin). Coronary angiography showed
tertiary coronary vasculature is evident. IVUS minimal lumen area  4.5 cm2,opy
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